Targeting NIPBL may offer a novel strategy to disrupt MYCN-driven transcription and promote tumor cell differentiation in MYCN-amplified neuroblastoma, ultimately improving therapeutic outcomes in this aggressive pediatric cancer. Here, MYCN is linked to cancer.